Zydus Cadila starts supply of Covid-19 vaccine ZyCoV-D to govt

ZyCoV-D is a three-dose vaccine administered intradermally

Zydus vaccine
Photo: Bloomberg
Press Trust of India New Delhi
1 min read Last Updated : Feb 02 2022 | 10:58 PM IST
Drug firm Zydus Cadila on Wednesday said it has commenced supplies of its Covid-19 vaccine ZyCoV-D to the central government. The company has initiated the supply as per the order placed by the government, the drug firm said in a statement. The group is also planning to make the vaccine available in the private market, it added.

ZyCoV-D is a three-dose vaccine administered intradermally.

"The vaccine will be priced at Rs 265 per dose and the applicator being offered at Rs 93 per dose, excluding GST," Zydus Cadila said.

The Ahmedabad-based drugmaker has also entered into a definitive agreement with Shilpa Medicare Ltd, a contract manufacturing organisation, to produce mutually agreeable doses of ZyCoV-D.

It has also entered into an agreement with Enzychem Lifesciences of the Republic of Korea for the manufacturing license and technology transfer for the Plasmid DNA Vaccine, Zydus Cadila noted.

ZyCoV-D is a Plasmid DNA vaccine that produces the spike protein of the SARS-CoV-2 virus and elicits an immune response mediated by the cellular and humoral arms of the human immune system, which play a vital role in protection from disease as well as viral clearance.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusOmicronDelta variant of coronavirusZydus CadilaCoronavirus VaccineCoronavirus TestsVaccination

Next Story